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ABSTRACT
Graves’ disease occurs predominantly in women. 
Epstein-Barr virus (EBV) mainly persists in human B 
lymphocytes, and its reactivation stimulates antibody 
production. We previously suggested that the EBV 
reactivation-induced production of TRAb and IgM at 
100 nM estradiol (pregnant level) was lower than that at 
0 nM estradiol and that class switch recombination may 
be increased by estradiol. In this study, we examined the 
effect of estradiol on EBV reactivation. We identified the 
expression of EBV-glycoprotein 350/220 (gp350/220) in 
the late phase of reactivation and plasma cell differentia-
tion of EBV-infected cells using 72A1 antibody and 
CD138 antibody, respectively. We found the mean ratio 
of gp 350/220(+) CD138(+) cells at 100 nM estradiol was 
higher than that at 0 nM estradiol. These results suggest-
ed that EBV-infected cells could survive with keeping 
the ability of antibody production in 100 nM estradiol, 
which is consistent with the improvement of Graves’ 
disease during maternity and exacerbation postpartum.
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Most autoimmune diseases predominantly occur in 
women and are influenced by various factors.1–5 Graves’ 
disease, an autoimmune hyperthyroidism, often goes 
into remission during pregnancy and becomes aggravat-
ed after delivery.6, 7 Estrogen regulates menstrual cycle 
and maternity and can stimulate antibody production 
from B cells.5, 8 Estradiol is the most potent estrogen.
Graves’ disease is caused by thyrotropin receptor 
antibody (TRAb), which overstimulates the thyroid-
stimulating hormone receptor. Nagata et al. reported 
that Graves’ disease patients and healthy controls have 
Epstein-Barr virus (EBV)-infected lymphocytes with 
TRAb on their surface in human peripheral blood mono-
nuclear cells (PBMCs); these PBMCs produce TRAb and 
the plasma cell population increases in response to reac-
tivation of EBV in vitro.9–11 In this study, we confirmed 
the presence of cells that were EBV-reactivated and 
plasma cell differentiated in healthy controls and Graves’ 
disease patients, and examined the effect of estradiol 
on the ratio of these cells. We discussed the effects of 
pregnancy level of estradiol on EBV reactivation.
MATERIALS AND METHODS
Subjects
PBMC samples were obtained from 3 healthy controls 
and 4 Graves’ disease patients diagnosed according to 
the guidelines of the Japan Thyroid Association (Table 
1). All subjects provided written informed consent, and 
the study protocol was approved by the Medical Ethics 
Committee for Human Subject Research (No. 707, 707-
1-13) at Faculty of Medicine, Tottori University, Yonago, 
Japan. The mean ages (± SD) of healthy controls and 
Graves’ disease patients were 35.3 (± 19.85) years and 
36.0 (± 4.24) years, respectively. One of the controls and 
all patients were female. Thyroid functions of the pa-
tients in Table 1 are clinical data. The levels of thyroid 
stimulating hormone (TSH), free thyroxine (FT4), and 
TRAb were measured by electro chemiluminescence 
immunoassay (ECLIA) (0.54–4.54 μIU/mL), ECLIA 
(0.97–1.72 ng/dL), and radio receptor assay (DYNOtest 
TRAb Human; Yamasa Corporation, Choshi, Japan) 
(1.0 IU/L >), respectively (normal range). Three patients 
were receiving treatment with antithyroid drugs (propyl-
thiouracil). Control subjects were enrolled voluntarily, 
their thyroid functions were normal, and they had no 
family history of thyroid disease.
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PBMC preparation
Peripheral blood samples were obtained from Graves’ 
disease patients and healthy controls. PBMCs were 
separated using a Ficoll-Conray density gradient and 
stored at –80 °C until use.
Estradiol
17β-estradiol (Sigma-Aldrich, Saint Louis, MO) was 
dissolved in ethanol to prepare a 1 mg/mL stock solu-
tion and stored at 4 °C until use. Estradiol was added to 
the medium and maintained at 0 nM, 1 nM, or 100 nM, 
which corresponds to control, mid-luteal, or pregnancy 
levels, respectively.
Sampling protocol
PBMCs were cultured at 37 °C for 2 days in RPMI 
1640/10% FBS with cyclosporine A (0.1 μg/mL) to 
inhibit T cell effects. PBMCs were transferred to an 
incubator at 33 °C to induce EBV reactivation and were 
regarded as day 0 samples. On days 0, 5, 10, and 12, half 
of the culture supernatant was sampled and replaced by 
fresh medium with estradiol, and the estradiol concen-
tration was maintained at 0 nM, 1 nM, or 100 nM.
Flowcytometry (FCM) and confocal laser scanning 
microscopy (CLSM)
On day 12 after EBV reactivation induction, the collect-
ed PBMCs of 3 healthy controls (No. 1–3) and 4 Graves’ 
disease patients (No. 4–7) were fixed by 2% parafor-
maldehyde and stored at 4 °C until use. We confirmed 
expression of EBV glycoprotein 350/220 (gp350/220) 
with anti-gp350/220 antibodies (72A1) and plasma cells 
with CD138 antibodies by FCM (No. 1–3 controls and 
No. 4–6 patients) and CLSM (No. 7 patient). gp350/220 
binds to CD21/CR2 on the B cell surface. gp350/220 is 
a late phase protein of EBV reactivation and is also de-
tected on the host cell membrane. We used the primary 
mouse monoclonal antibody 72A1 (Millipore, Billenca, 
MA) to detect gp350/220 and goat anti-mouse IgG 
H&L (Alexa Fluor 488) (Abcam, Cambridge, Britain) 
as a secondary antibody. Differentiation to plasma cells 
was detected by adding anti-human CD138 mouse IgG-
Alexa Fluor 647 conjugated (AbD Serotec, Raleigh, 
NC). FCM analysis was performed using a Gallios ana-
lyzer (Beckman Coulter, Fullerton, CA). Gp350/220(+) 
CD138(+) cells were sorted with the cell sorter MoFlo 
XDP (Beckman Coulter) and examined by CLSM with 
TCS SP-2 (Leica, Wetzlar, Germany).
Statistical analysis
We adopted one-way ANOVA (SPSS statistics, IBM, 
Armonk, NY) to analyze the variation of the mean ratio 
of gp350/220(+) CD138(+) cell percentages.
RESULTS
Culture cells on day 12 after EBV reactivation con-
tained gp350/220(+) CD138(+) double-positive cells
We detected gp350/220(+) CD138(+) double-positive 
cells in PBMCs of healthy controls (No. 1–3) and 
patients (No. 4–6) by FCM (Fig. 1). No. 2 and No. 3 are 
additional male subjects for FCM. The flowcytometer 
displays the cell percentages as the relative number 
against the lymphocyte population. To compare the ef-
fects of different estradiol concentrations, we examined 
the ratios of cell percentages at each estradiol concentra-
tion to that at 0 nM estradiol. In healthy controls and pa-
tients, the ratio of gp35/220(+) CD138(+) double-positive 
cells in culture with 100 nM estradiol was larger than 
Table 1. Subject profiles
No. Sex Age (years)
Treatment  
(for 1 day)
TSH  
(μIU/L)
FT4  
(ng/dL)
TRAb  
(IU/L) Allergy
Controls 1 F 27 – nt nt nt –
2 M 58 – nt nt nt –
3 M 21 – nt nt nt –
Mean 35.3
Patients 4 F 30 PTU 100 mg 2.03 1.32 3.3 –
(Graves’ disease) 5 F 39 – 1.75 1.19 6.9 –
6 F 36 PTU 50 mg 1.11 1.18 0.3 > –
7 F 39 PTU 150 mg 4.65 0.96 15.0 bronchial asthma,  atopic dermatitis
Mean 36.0 2.39 1.16 6.30
F, female; FT4, free thyroxine; M, male; nt, not tested; PTU, propylthiouracil; TRAb, thyrotropin receptor antibody; TSH, thyroid 
stimulating hormone.
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Fig. 1. Detection of gp350/220(+) CD138(+) double-positive cells in culture cells on day 12.
(A) Analysis of the population of gp350/220(+) CD138(+) double-positive cells in culture cells on day 12 by FCM (ratios of cell percent-
age at each estradiol concentration to that at 0 nM estradiol). No. 1–3 are controls, and No. 4–6 are patients. Two controls (No. 2 and 
3) were male subjects for FCM. The bar chart shows the ratio of gp350/220(+) CD138(+) double-positive cells. The line graph showed 
the averages +/− standard error of the ratio of gp350/220(+) CD138(+) double-positive cells of 3 controls and 3 patients. Gp350/220(+) 
CD138(+) double-positive cell population was increased by addition of 100 nM estradiol (P = 0.055 in one-way ANOVA).
(B) Detection of gp350/220(+) CD138(+) double-positive cells in culture cells on day 12 using CLSM. Culture cells of patient No. 7 ex-
pressing gp350/220 in the cytoplasm and cell surface and CD138 on the surface. (a) Alexa Fluor488 (green) representing EBV gp350/220 
was detected overall of the cells. 72A1 is the antibody against gp350/220. (b) Alexa648 (red spots) representing CD138 was observed on 
the surface of the cells. (c) DAPI (blue) represents the cell nucleus. (d) Merge of (a), (b), and (c).
Avg., average; CLSM, confocal laser scanning microscopy; DAPI, 4’, 6-Diamidino-2-phenylindole; FCM, Flowcytometry; Gp350/220, 
glycoprotein 350/220.
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that of cultures with 0 nM or 1 nM estradiol (P = 0.055) 
(Fig. 1A).
We observed gp350/220(+) CD138(+) double-
positive cells by confocal laser microscope, and noted 
red spots of CD138 on cell surfaces and fine green dots 
of 72A1 in the cytoplasm and cell surfaces of patient 
No. 7 (Fig. 1B).
DISCUSSION
We found that the mean ratio of gp350/220(+) CD138(+) 
cells at 100 nM estradiol was higher than that at 0 nM 
estradiol. The result of CLSM indicated the presence 
of EBV-reactivated and plasma cell differentiated cells 
(Fig. 1). However, in our previous study, production of 
TRAb and IgM at 100 nM estradiol is lower than that at 
0 nM estradiol,12 which seems to contradict our current 
data, but we often observed abundant antibodies in 
culture supernatant in plate wells with only a few cells. 
In our previous study (0 nM estradiol), the percentage 
of gp350/220(+) cells or CD138(+) cells increased at day 
12 compared with day 0 of reactivation.10, 11 However, 
in the present study, the ratio of gp350/220(+) CD138(+) 
cells further increased on day 12 in culture with 100 
nM estradiol, which suggests that there were less dead 
cells that had completed releasing antibodies than that 
at 0 nM estradiol. EBV-infected cells may survive with 
keeping the ability of antibody production in 100 nM 
estradiol culture.
EBV-infected cells could survive with keeping the 
ability of antibody production at high concentrations of 
estradiol, which suggests that EBV induces a survival 
signal. For instance, EBV-latent membrane protein 1 ac-
tivates nuclear factor κB and induces the expression of 
anti-apoptotic B-cell lymphoma 2 (Bcl-2). Bcl-2 proteins 
are related to the survival of gp350/220(+) CD138(+) 
cells, and further experiments are needed to confirm 
this possibility.
We found that EBV-reactivated and plasma cell 
differentiated cell percentages increased under high 
estradiol concentrations, which could result in decreas-
ing production of antibodies. If estradiol concentration 
decreased again, cells may produce antibodies. The 
present results and our previous results showing that 
high estradiol concentrations decrease TRAb and IgM 
production are consistent with the clinical observations 
of improvement of Graves’ disease during maternity 
and exacerbation postpartum.6, 12, 13
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